KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 65 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $999,536 | +12.0% | 103,794 | +4.7% | 0.00% | +50.0% |
| Q2 2023 | $892,458 | +108.9% | 99,162 | +82.4% | 0.00% | +100.0% |
| Q1 2023 | $427,309 | +263.0% | 54,365 | +212.2% | 0.00% | – |
| Q4 2022 | $117,732 | -68.1% | 17,416 | -53.5% | 0.00% | -100.0% |
| Q2 2022 | $369,000 | -71.4% | 37,453 | -61.6% | 0.00% | -66.7% |
| Q4 2021 | $1,291,000 | -39.7% | 97,592 | -20.4% | 0.00% | -40.0% |
| Q3 2021 | $2,140,000 | +57.0% | 122,643 | +115.6% | 0.01% | +66.7% |
| Q2 2021 | $1,363,000 | -34.2% | 56,878 | -29.5% | 0.00% | -40.0% |
| Q1 2021 | $2,072,000 | +284.4% | 80,673 | +184.1% | 0.01% | +150.0% |
| Q4 2020 | $539,000 | +63.3% | 28,396 | +4.2% | 0.00% | 0.0% |
| Q2 2020 | $330,000 | +8.9% | 27,262 | +99.1% | 0.00% | +100.0% |
| Q2 2019 | $303,000 | +7.4% | 13,696 | +7.5% | 0.00% | 0.0% |
| Q3 2018 | $282,000 | – | 12,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |